Research-backed guides to peptides and health-optimization stacks — recovery, metabolic health, skin & hair, longevity. Real research, plain-English answers, and a source link on every claim. Then find research-grade suppliers.
New here? Start with the one-page map — the most-used peptide stacks, what the research actually says, and what to check before you buy.
No spam. Unsubscribe anytime.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
Read the full update →
Not sure where to start? Jump to the peptides studied for the goal you care about — recovery, metabolism, skin, and more.
The metabolic peptides behind the weight-management wave — GLP-1 and next-generation agonists — grouped with a neutral look at the evidence and how they differ. Every claim is sourced on each peptide's guide.
Explore this guide →
The peptides most discussed for tendon, ligament, muscle, and gut repair — grouped so you can see how they differ and where the research stands. Every claim is sourced on each peptide's own guide.
Explore this guide →
Peptides studied for skin regeneration, collagen, and hair — led by the copper peptide GHK-Cu. A neutral, sourced overview linking to each peptide's full guide.
Explore this guide →
Peptides studied for immune modulation and inflammatory balance — thymic and anti-inflammatory peptides — with a neutral look at the evidence. Every claim is sourced on each peptide's guide.
Explore this guide →
The peptides studied for amplifying the body's natural growth-hormone pulse — GHRH analogs and GHRPs — grouped so you can see how they differ and where the research stands. Every claim is sourced on each peptide's own guide.
Explore this guide →
Peptides and cofactors studied in cellular-aging, mitochondrial, and NAD+ research — grouped for a neutral look at where the science stands (much of it preclinical). Every claim is sourced on each peptide's guide.
Explore this guide →
Ranked by the depth of published research behind them — every claim links to a study you can verify yourself.
Semaglutide is a medicine that copies a natural body hormone called GLP-1.…
Learn more →
Tirzepatide is a man-made copy of two natural gut hormones.…
Learn more →
BPC-157 is a man-made copy of a tiny piece of protein found in the juice of your stomach.…
Learn more →
Thymosin Alpha-1 is a small protein made naturally in the body.…
Learn more →
Retatrutide is a lab-made copy of natural body chemicals that control hunger.…
Learn more →
GHK-Cu is a small piece of protein that is naturally found in your body.…
Learn more →
BPC-157 + TB-500 — the most talked-about peptide combination in recovery research. Learn the science, see the sourced evidence, and compare suppliers.

Our content is built from PubMed studies, clinical guidelines, and established references — not marketing copy. Click any citation to verify it yourself.
Evidence-backed guides on peptides and stacks — with PubMed citations and a source link for every claim.
Explore our full library — benefits, side effects, and the research behind each compound, all in one place.
Our supplier pages list published COAs, price per mg, and clearly disclosed affiliate links.
This journal listing includes several articles touching on obesity pharmacotherapy, most notably a systematic review and meta-analysis of subcutaneous semaglutide's effects on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Additional items examine GLP-1 receptor agonists from a rheumatological perspective and self-medication with GLP-1 drugs among Brazilian adults. The listing also covers broader obesity research, including bariatric surgery positioning and epidemiological studies.
New research suggests that semaglutide reduces the risk of major adverse cardiovascular events (MACE) not only through weight loss but also by lowering systemic inflammation. A study of over 17,000 patients found that reductions in the inflammatory biomarker hs-CRP accounted for roughly 28% of the drug's cardiovascular benefit. This indicates that semaglutide's mechanism for heart protection involves direct anti-inflammatory effects independent of glycemic control or body weight reduction.
The FDA has granted accelerated approval to Bristol Myers Squibb's iberdomide, marketed as Zenbexus, for relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab. As a first-in-class CELMoD agent, iberdomide is a cereblon-modulating peptide-like molecule that induces targeted protein degradation to eliminate cancer-driving proteins. The approval was supported by Phase 3 data showing a statistically significant improvement in minimal residual disease-negative complete response rates compared to standard care.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.